placebo in combination with carboplatin and paclitaxel as first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) with negative driver genes. The results show that the 5-year ...

Objective: This study aims to evaluate the prognostic significance of peripheral blood biomarkers in relation to outcomes and immune-related adverse events (irAEs) among patients with stage IV driver ...

Background: Lung squamous cell carcinoma (LUSC) is a malignant disease associated with poor therapeutic responses and prognosis. Preliminary studies have shown that the dysregulation of long ...